# LUBio Science

> LUBio Science is a VC fund backing Therapeutics and Biotechnology. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 1
- Last investment: Jul 2013
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.lubio.ch

LUBio Science is a VC fund focused on Therapeutics and Biotechnology. LuBioScience was founded at the end of 2004 and started being operationally active by the 1st of January 2005. It was established out of the former Juro Supply GmbH, a well known and successfully operating specialist in the distribution of Life Science reagents and products Europe wide. Today we are located in Lucerne, the centre of Switzerland,where we administrate our major stock. Beside our focus on our home market Switzerland, we maintain strong relationships and contacts throughout Europe. With over 30 years of experience in Marketing & Sales of Life Science Reagents in Switzerland and Europe, we know our clients and our suppliers’ expectations, needs and requirements. Our experienced and motivated team stands for efficiency and professional service.

## Contacts

5 contacts available for LUBio Science. Shizune tracks 2 team members at LUBio Science. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lubio-science?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Medical Device | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Roland Schärli | Managing Director | 0 | https://shizune.co/investors/profile/roland-schrli |
| Tobias Dietschy | Marketing & Sales Director | 0 | https://shizune.co/investors/profile/tobias-dietschy |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cantargia | The company is based on the original discovery that leukemic stem cells in patients with chronic myeloid leukemia (CML) express a cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. Stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) has also beenshown to have and upregulation of the receptor. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia | $1M |  | Jul 05, 2013 |  |

1 of 1 investments shown.

## Co-investors
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Chalmers Ventures AB](https://shizune.co/investors/profile/chalmers-ventures) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Sweden](https://shizune.co/investors/biotechnology-investors-sweden)
- [Biotech Investors in Sweden](https://shizune.co/investors/biotech-investors-sweden)
- [Medical Device Investors in Sweden](https://shizune.co/investors/medical-device-investors-sweden)
- [Medical Device VC Funds in Sweden](https://shizune.co/investors/medical-device-vc-funds-sweden)
- [Biotechnology VC Funds in Sweden](https://shizune.co/investors/biotechnology-vc-funds-sweden)
- [Biotech VC Funds in Sweden](https://shizune.co/investors/biotech-vc-funds-sweden)

## FAQ

### What does LUBio Science invest in?

LUBio Science invests primarily in Therapeutics, Biotechnology and Medical Device startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LUBio Science?

Public channels for LUBio Science include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LUBio Science?

The team at LUBio Science includes Roland Schärli (Managing Director) and Tobias Dietschy (Marketing & Sales Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co